Want to see AU:EZZ full AI Analyst Report?
EZZ Stock Chart & Stats
AU$0.64
-AU$0.02(-3.88%)
At close: 4:00 PM EDT
AU$0.64
-AU$0.02(-3.88%)
Day’s Range― - ―
52-Week RangeAU$0.36 - AU$3.38
Previous CloseN/A
Volume16.90K
Average Volume (3M)17.25K
Market Cap
AU$19.52M
Enterprise ValueAU$7.93
Total Cash (Recent Filing)AU$9.72M
Total Debt (Recent Filing)AU$478.59K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.8%
Share Statistics
EPS (TTM)-0.11
Shares Outstanding47,043,200
10 Day Avg. Volume18,046
30 Day Avg. Volume17,251
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.70
Price to Sales (P/S)0.37
P/FCF Ratio-1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)AU$105.10M
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageVery low leverage limits debt-related financial risk and preserves flexibility during operating volatility. A sizable equity base gives EZZ more capacity to manage a downturn, support working capital, and pursue recovery without relying heavily on additional borrowing.
Healthy Gross Margin HistoryA still-healthy gross margin and history of profitability indicate that EZZ has previously demonstrated viable underlying economics. If revenue and product mix recover, this earnings base could support renewed profitability and improve the quality of future cash generation.
Multi-Channel Branded ModelThe branded product model reaches customers through direct online sales, trade channels, and overseas markets. This channel breadth can support durable market access and reduce reliance on a single route to customers, provided demand and regulatory access remain supportive.
Bears Say
Revenue And Earnings DeteriorationThe sharp revenue decline and move into loss signal a material weakening in demand, execution, or product economics. Sustained contraction would reduce operating scale and investment capacity, making recovery in earnings and shareholder returns more dependent on reversing the downturn.
Negative Cash GenerationCash consumption while reporting a loss increases funding and execution risk, even though leverage is currently low. If negative operating and free cash flow persists, EZZ may have less flexibility to fund products, marketing, working capital, or other growth initiatives internally.
Gross-Margin CompressionLower gross margin weakens the profitability of each sale and leaves less room to absorb operating costs. Combined with negative operating profit, the compression suggests that pricing, product mix, or cost conditions have become less favorable and could constrain earnings recovery.
EZZ Life Science Holdings Ltd. News
EZZ FAQ
What was EZZ Life Science Holdings Ltd.’s price range in the past 12 months?
EZZ Life Science Holdings Ltd. lowest share price was AU$0.35 and its highest was AU$3.38 in the past 12 months.
What is EZZ Life Science Holdings Ltd.’s market cap?
EZZ Life Science Holdings Ltd.’s market cap is AU$19.52M.
When is EZZ Life Science Holdings Ltd.’s upcoming earnings report date?
EZZ Life Science Holdings Ltd.’s upcoming earnings report date is Mar 01, 2027 which is in 162 days.
How were EZZ Life Science Holdings Ltd.’s earnings last quarter?
EZZ Life Science Holdings Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.1 earnings per share for the quarter.
Is EZZ Life Science Holdings Ltd. overvalued?
According to Wall Street analysts EZZ Life Science Holdings Ltd.’s price is currently Overvalued.
Does EZZ Life Science Holdings Ltd. pay dividends?
EZZ Life Science Holdings Ltd. pays a Semiannually dividend of AU$0.02 which represents an annual dividend yield of 9.8%. See more information on EZZ Life Science Holdings Ltd. dividends here
What is EZZ Life Science Holdings Ltd.’s EPS estimate?
EZZ Life Science Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EZZ Life Science Holdings Ltd. have?
EZZ Life Science Holdings Ltd. has 47,043,200 shares outstanding.
What happened to EZZ Life Science Holdings Ltd.’s price movement after its last earnings report?
EZZ Life Science Holdings Ltd. reported an EPS of -AU$0.1 in its last earnings report. Following the earnings report the stock price went down -8.594%.
Which hedge fund is a major shareholder of EZZ Life Science Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:EZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EZZ Life Science Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:EZZ Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth AU$14.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.02%
12-Months-Change
Fundamentals
Return on Equity
9.80%
Trailing 12-Months
Asset Growth
-18.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territories. The company's operations are divided into two distinct segments: 'Brought in Lines' and 'Company Owned products.' EZZ is actively involved in the wholesale supply of its EAORON-branded skincare portfolio, distributing it to pharmacies, major supermarkets, specialist retailers, and general grocery stores. Furthermore, the company designs, develops, manufactures, and markets a comprehensive selection of consumer health products under its own EZZ brand. This extensive offering includes vitamins, dietary supplements, sports nutrition, weight management and wellbeing solutions, traditional herbal remedies, and paediatric lines. These EZZ-branded items are sold directly to consumers via its e-commerce platforms and various retail stores, notably Tmall Global. Founded in 2015, EZZ Life Science Holdings Limited maintains its corporate headquarters in Silverwater, Australia.
Technical Analysis
Zelira Therapeutics
―
Immuron Limited
―
Anatara Lifesciences Ltd
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―